Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

Who May Qualify: - Male or female participants aged ≥18 years at the time of randomization. - Clinical diagnosis of plaque psoriasis with Psoriasis Area and Severity Index (PASI) ≥3 and body surface area (BSA) ≥3%. - Body mass index (BMI) ≥25 kg/m², consistent with overweight or obesity. - Participants with or without type 2 diabetes mellitus. - Participants with diabetes must be on stable antidiabetic therapy (no changes in medication or dosage within the previous 3 months) and have adequate glycemic control, defined as HbA1c ≤9.0% at baseline. - No use of systemic psoriasis therapies (e.g., methotrexate, cyclosporine) for at least 8 weeks prior to randomization. - No use of biologic therapies for at least 3 months prior to randomization. Who Should NOT Join This Trial: - Diagnosis of a non-plaque psoriasis subtype, including pustular, guttate, nail, inverse, psoriatic arthritis, or erythrodermic psoriasis. - Pregnancy or breastfeeding at the time of screening or enrollment. - Insulin-dependent diabetes mellitus or current use of sulfonylureas. - Active malignancy at the time of screening. - History of thyroid neoplasia. - Presence of autoimmune conditions (where your immune system attacks your own body)s. - Use of systemic therapies within 8 weeks prior to randomization. - Use of biologic therapies within 3 months prior to randomization. - Renal insufficiency. - Heart failure. - Hepatic insufficiency. - History of pancreatitis. - Current treatment with other GLP-1 receptor agonists. - History of inflammatory bowel disease. - Known allergy to starch. Always talk to your doctor about whether this trial is right for you.